Roche Reports Strong Half-Year Growth in 2025

Roche Holding AG ( (RHHBY) ) has released its Q2 earnings. Here is a breakdown of the information Roche Holding AG presented to its investors.

Roche Holding AG is a leading global healthcare company based in Switzerland, specializing in pharmaceuticals and diagnostics, known for its innovative approach in the life sciences sector. In its half-year report for 2025, Roche reported a significant increase in sales and profits, with a 7% growth in sales and a 23% rise in net income at constant exchange rates. The Pharmaceuticals Division saw a 10% increase in sales, driven by strong performances from key drugs like Phesgo, Xolair, and Hemlibra, while the Diagnostics Division maintained stable sales despite challenges in China. Roche’s core operating profit grew by 11% at constant exchange rates, reflecting effective cost management and strategic investments in research and development, particularly in oncology and neurology. However, the company faced a decrease in free cash flow by 37% due to increased tax payments and investments in collaborations. Looking ahead, Roche remains focused on innovation and strategic growth, with management optimistic about sustaining its market position despite ongoing challenges from biosimilar competition.